Iovance Biotherapeutics (IOVA) Interest Expenses (2011 - 2026)

Iovance Biotherapeutics (IOVA) has reported Interest Expenses for 16 consecutive years, with $2.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 11634.63% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $2.6 billion (up 11634.63% YoY), while the FY2025 annual figure was $893.0 million, up 859.42% from the prior year.
• Interest Expenses climbed to $2.6 billion in Q1 2026 per IOVA's latest filing, from $3.9 million in the prior quarter.
• Across five years, Interest Expenses topped out at $2.6 billion in Q1 2026 and bottomed at -$8.6 million in Q4 2023.
• Historically, Interest Expenses has averaged $223.5 million across 5 years, with a median of $22.0 million in 2025.
• Annual changes were most pronounced in 2023 — Interest Expenses soared 19725.6% — and 2024, when it slumped 99.04%.
• Iovance Biotherapeutics' Interest Expenses stood at -$7.3 million in 2022, then slipped by 18.48% to -$8.6 million in 2023, then jumped by 158.53% to $5.0 million in 2024, then decreased by 23.12% to $3.9 million in 2025, then surged by 66591.24% to $2.6 billion in 2026.
• Business Quant data shows IOVA's Interest Expenses at $2.6 billion in Q1 2026, $3.9 million in Q4 2025, and $156.6 million in Q3 2025.